Wall Street Associates’s Alexion Pharmaceuticals ALXN Stock Holding History

Wall Street Associates’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$245K	Hold	2,000	–	–	0.16%	191
2016 Q3	$245K	Hold	2,000	–	–	0.08%	208
2016 Q2	$234K	Hold	2,000	–	–	0.09%	204
2016 Q1	$278K	Hold	2,000	–	–	0.12%	187
2015 Q4	$381K	Hold	2,000	–	–	0.11%	240
2015 Q3	$313K	Hold	2,000	–	–	0.06%	289
2015 Q2	$362K	Hold	2,000	–	–	0.03%	302
2015 Q1	$347K	Hold	2,000	–	–	0.03%	295
2014 Q4	$370K	Hold	2,000	–	–	0.04%	277
2014 Q3	$332K	Sell	2,000 -2,965	-60%	-$487K	0.03%	295
2014 Q2	$776K	Sell	4,965 -700	-12%	-$111K	0.07%	232
2014 Q1	$862K	Hold	5,665	–	–	0.07%	223
2013 Q4	$753K	Sell	5,665 -40	-0.7%	-$4.8K	0.06%	238
2013 Q3	$663K	Sell	5,705 -100	-2%	-$11K	0.06%	239
2013 Q2	$535K	Buy	+5,805	New	+$559K	0.05%	232

Other funds holding ALXN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Wall Street Associates's ALXN Position: Q4 2016 in Review

Wall Street Associates held its Alexion Pharmaceuticals (ALXN) position steady in Q4 2016 at 2,000 shares worth $245K. The position accounts for 0.16% of the portfolio, ranked #191.

Wall Street Associates first reported a position in ALXN in Q2 2013 and has held it in 15 quarters since. The position peaked at $862K in Q1 2014. 548 funds tracked by Wall St. Rank hold ALXN as of Q4 2016.

Wall Street Associates held 2,000 shares of Alexion Pharmaceuticals worth $245K as of Q4 2016.
Wall Street Associates left its Alexion Pharmaceuticals share count unchanged in Q4 2016.
Alexion Pharmaceuticals made up 0.16% of Wall Street Associates's portfolio in Q4 2016, its #191 holding.
Wall Street Associates first reported a position in Alexion Pharmaceuticals in Q2 2013 and has held it in 15 quarters since.
Wall Street Associates's Alexion Pharmaceuticals position peaked at $862K in Q1 2014.
548 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2016.

Based on Wall Street Associates's 13F filing for Q4 2016, filed 18 Jan 2017.